Gln --> Arg 191 Polymorphism of Paraoxonase and Parkinson's Disease

Overview

Journal Hum Hered

Specialty Genetics

Date 1999 Jun 12

PMID 10364684

Citations 8

Authors

S Akhmedova

S Anisimov

A Yakimovsky

E Schwartz

Affiliations

Soon will be listed here.

Abstract

We investigated the Gln --> Arg 191 polymorphism in paraoxonase (PON1) in St. Petersburg population, in three clinically differentiated groups of patients with Parkinson's disease (PD) and in the symptomatic tremor group. A new approach for Gln --> Arg 191 PON1 polymorphism genotyping is suggested. No significant differences in the groups studies as compared to the controls was observed.

Citing Articles

Quantitative and causal analysis for inflammatory genes and the risk of Parkinson's disease.

Yi M, Li J, Jian S, Li B, Huang Z, Shu L Front Immunol. 2023; 14:1119315.

PMID: 36926335 PMC: 10011457. DOI: 10.3389/fimmu.2023.1119315.

HDL Accessory Proteins in Parkinson's Disease-Focusing on Clusterin (Apolipoprotein J) in Regard to Its Involvement in Pathology and Diagnostics-A Review.

Berdowska I, Matusiewicz M, Krzystek-Korpacka M Antioxidants (Basel). 2022; 11(3).

PMID: 35326174 PMC: 8944556. DOI: 10.3390/antiox11030524.

Paraoxonase Role in Human Neurodegenerative Diseases.

Reichert C, Levy D, Bydlowski S Antioxidants (Basel). 2020; 10(1).

PMID: 33374313 PMC: 7824310. DOI: 10.3390/antiox10010011.

Paraoxonase 1, agricultural organophosphate exposure, and Parkinson disease.

Manthripragada A, Costello S, Cockburn M, Bronstein J, Ritz B Epidemiology. 2009; 21(1):87-94.

PMID: 19907334 PMC: 3117899. DOI: 10.1097/EDE.0b013e3181c15ec6.

Paraoxonase 1 polymorphisms are not related with the risk for multiple sclerosis.

Martinez C, Garcia-Martin E, Benito-Leon J, Calleja P, Diaz-Sanchez M, Pisa D Neuromolecular Med. 2009; 12(3):217-23.

PMID: 19826962 DOI: 10.1007/s12017-009-8095-9.